Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Characteristics of Covid-19 in Patients With Multiple Sclerosis Publisher Pubmed



Ghadiri F1 ; Sahraian MA1 ; Shaygannejad V2 ; Ashtari F2 ; Ghalyanchi H3 ; Baghbanian SM4 ; Mojdehipanah H5 ; Majdinasab N6 ; Hosseini S7 ; Poursadeghfard M8 ; Beladimoghadam N9 ; Razazian N10 ; Ayoubi S1 ; Rezaeimanesh N1 Show All Authors
Authors
  1. Ghadiri F1
  2. Sahraian MA1
  3. Shaygannejad V2
  4. Ashtari F2
  5. Ghalyanchi H3
  6. Baghbanian SM4
  7. Mojdehipanah H5
  8. Majdinasab N6
  9. Hosseini S7
  10. Poursadeghfard M8
  11. Beladimoghadam N9
  12. Razazian N10
  13. Ayoubi S1
  14. Rezaeimanesh N1
  15. Eskandarieh S1
  16. Naser Moghadasi A1
Show Affiliations
Authors Affiliations
  1. 1. Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Hassan Abad square, Tehran, Iran
  2. 2. Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Department of Neurology, Poursina Hospital, Guilan University of Medical Sciences, Rasht, Iran
  4. 4. Department of Neurology, Booalicina Hospital, Mazandaran University of Medical Sciences, Sari, Iran
  5. 5. Department of Neurology, Qazvin University of Medical Sciences, Qazvin, Iran
  6. 6. Musculoskeletal Rehabilitation Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
  7. 7. Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
  8. 8. Department of Neurology, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
  9. 9. Department of Neurology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  10. 10. Department of Neurology, Medicine Faculty, Kermanshah University of Medical Sciences, Kermanshah, Iran

Source: Multiple Sclerosis and Related Disorders Published:2022


Abstract

Background: Regarding the high prevalence of multiple sclerosis (MS) and COVID-19 in Iran, a multicenter study of COVID-19 in Iranian MS patients with is carried out to address the concerns of this population. Methods: Data on MS patients with COVID-19 from nine provinces of Iran were entered in a web-based registry system, between July 2020 and March 2021. Among the COVID-19 symptoms, dyspnea, altered mental status, or those resulting in hospital admission were considered severe. Results: A total of 397 eligible patients were identified. In addition, 310 (78%) were female. The mean age was 36.5 ± 9.5. 294 (74%) patients had relapsing- remitting form. Also, four patients (1%) expired due to COVID-19 infection. The mean duration of admission in hospitalized patients was 9 (± 5.3) days. MRI was performed on 111 (28%) patients after developing COVID-19. MRI changes were observed in 27 (24%) of these cases. MS drug was changed in 26 (6%) patients. Steroid use in the past three months (OR: 2.43, 95% CI: 1.003–5.88) (p value: 0.049) and antiCD20s (OR: 4.03, 95% CI: 2.41–6.68) (p value < 0.001) showed significant association with severe COVID-19 symptoms. Conclusion: The death rate of COVID-19 among MS patients (1%) is lower than the overall death rate of the pandemic in Iran (3%). Those who received steroid in the past three months may be at increased risk of more severe forms of COVID-19. There are still doubts about the effect of anti CD20s on COVID-19 severity. © 2021 Elsevier B.V.
Related Docs
View other Related Docs
1. Covid-19 Infection and Hospitalization Rate in Iranian Multiple Sclerosis Patients: What We Know by May 2021, Multiple Sclerosis and Related Disorders (2022)
2. The Prevalence of Covid-19 Infection in Patients With Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, Neurological Sciences (2021)
3. Covid-19 Among Patients With Multiple Sclerosis a Systematic Review, Neurology: Neuroimmunology and NeuroInflammation (2021)
4. Covid-19 Susceptibility and Outcomes Among Patients With Neuromyelitis Optica Spectrum Disorder (Nmosd): A Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2022)
5. Risk Factors of Severe Covid-19 in People With Multiple Sclerosis : A Systematic Review and Meta-Analysis, Revue Neurologique (2022)
6. Predictors of Catching Covid-19 Infection During Pandemic Stage in Patients With Multiple Sclerosis (Ms), International Journal of Preventive Medicine (2022)
7. Disease-Modifying Therapies, Outcomes, Risk Factors and Severity of Covid-19 in Multiple Sclerosis: A Menactrims Registry Based Study, Multiple Sclerosis and Related Disorders (2024)
8. Multiple Sclerosis Is Associated With Worse Covid-19 Outcomes Compared to the General Population: A Population-Based Study, Multiple Sclerosis and Related Disorders (2023)
Experts (# of related papers)
View all Related Experts
Vahid Shaygannejad (79)
Masoud Etemadifar (67)
Other Related Docs
9. Prevalence of Multiple Sclerosis (Ms) in Iran: A Systematic Review and Meta-Analysis, Neurological Sciences (2022)
10. Prevalence and Incidence of Multiple Sclerosis in Isfahan, Iran Between 1996 and 2021: A Population-Based Study, Multiple Sclerosis and Related Disorders (2024)
11. The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations During the Covid-19 Pandemic, Biomolecules (2021)
12. Ongoing Increase in Incidence and Prevalence of Multiple Sclerosis in South-Eastern Iran: A Three Decade Study, Multiple Sclerosis and Related Disorders (2023)
13. Epidemiology of Familial Multiple Sclerosis in Iran: A National Registry-Based Study, BMC Neurology (2022)
14. Time Interval Between the Onset of Symptoms and Diagnosis of Multiple Sclerosis and the Influential Factors: A National Registry-Based Study, Clinical Neurology and Neurosurgery (2024)
15. Fear of Re-Infection, Relapse, and Anxiety During Covid-19 Pandemic in Patients With Multiple Sclerosis: A Multi-Center Study, Current Journal of Neurology (2023)
16. A Multi-Centre Longitudinal Study Analysing Multiple Sclerosis Disease-Modifying Therapy Prescribing Patterns During the Covid-19 Pandemic, Journal of Neurology (2024)
17. Epidemiology of Multiple Sclerosis in Iran: A Systematic Review, European Neurology (2013)
18. Estimated Prevalence and Incidence of Multiple Sclerosis in Iran, European Neurology (2014)
19. Does Covid-19 Increase the Long-Term Relapsing-Remitting Multiple Sclerosis Clinical Activity? a Cohort Study, BMC Neurology (2022)
20. Sharp Increase in the Incidence and Prevalence of Multiple Sclerosis in Isfahan, Iran, Multiple Sclerosis Journal (2011)
21. Comparing the Consequences of Covid-19 Vaccination Between Central Nervous System (Cns) Demyelinating Diseases and Other Neurological Disorders, Vaccine (2024)
22. Impact of the Covid-19 Pandemic on the Psychological Status and Cortisol Level of Multiple Sclerosis Patients, Neuropsychological Rehabilitation (2023)
23. Effect of Multiple Sclerosis Disease-Modifying Therapies on the Real-World Effectiveness of Two Doses of Bbibp-Corv (Sinopharm) Vaccine, Journal of the Neurological Sciences (2023)
24. Multiple Sclerosis in Isfahan, Iran, International Review of Neurobiology (2007)
25. Prevalence of Multiple Sclerosis in Isfahan, Iran, Neuroepidemiology (2006)
26. Prescription Trends of Disease-Modifying Treatments for Multiple Sclerosis in Iran Over the Past 30 Years, Multiple Sclerosis and Related Disorders (2022)
27. Outcome of Covid-19 Infection in Multiple Sclerosis Patients Receiving Disease-Modifying Therapies, Journal of Research in Medical Sciences (2021)
28. Favorable Outcome After Covid-19 Infection in a Multiple Sclerosis Patient Initiated on Ocrelizumab During the Pandemic, Multiple Sclerosis and Related Disorders (2020)
29. Assessment of Mental Health, Knowledge, and Attitude of Patients With Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder in Response to 2019 Novel Coronavirus, Neurological Sciences (2021)
30. Economic and Social Standing of Individuals in Iran Diagnosed With Multiple Sclerosis, Archives of Iranian Medicine (2023)
31. Multiple Sclerosis Epidemiology in Asia and Oceania; a Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2021)
32. Multiple Sclerosis (Ms) and Neuromyelitis Optica Spectrum Disorder (Nmosd) Following Covid-19 Vaccines: A Systematic Review, Revue Neurologique (2023)
33. Epidemiological Status and Health System Screening of Covid 19 Hospitalized Patients in Isfahan, Iran, Medical Journal of the Islamic Republic of Iran (2022)
34. A Report of Multiple Sclerosis Patients Treated by Cinnovex™ in Iran, Tehran University Medical Journal (2010)
35. Prevalence of Multiple Sclerosis in Iranian Emigrants: Review of the Evidence, Neurological Sciences (2016)
36. Characteristics of Covid-19 Disease in Multiple Sclerosis Patients, Multiple Sclerosis and Related Disorders (2020)
37. The Correlation Between Rituximab Dose Reduction and Acute Relapses of Neuromyelitis Optica Spectrum Disorder, Lessons From Covid-19 Epidemic, Multiple Sclerosis and Related Disorders (2024)
38. Prevalence of Coronavirus Disease 2019 in Patients With Neuromyelitis Optica in Isfahan, Iran, and a Review on Recent Reports and Literature, Current Journal of Neurology (2021)
39. Covid-19 and the Risk of Relapse in Multiple Sclerosis Patients: A Fight With No Bystander Effect?, Multiple Sclerosis and Related Disorders (2021)
40. Intravenous Methylprednisolone Pulse As a Treatment for Hospitalised Severe Covid-19 Patients: Results From a Randomised Controlled Clinical Trial, European Respiratory Journal (2020)
41. Childhood-Onset Multiple Sclerosis: Report of 82 Patients From Isfahan, Iran, Archives of Iranian Medicine (2007)
42. Incidence and Prevalence of Multiple Sclerosis in Persian Gulf Area: A Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2020)
43. Risk and Severity of Sars-Cov-2 Reinfection Among Patients With Multiple Sclerosis Vs. the General Population: A Population-Based Study, BMC Neurology (2022)
44. Does Early-Onset Multiple Sclerosis Differ From Adult-Onset Form in Iranian People, Journal of Research in Medical Sciences (2010)
45. Clinical and Epidemiological Aspects of Multiple Sclerosis in Children, Iranian Journal of Child Neurology (2017)
46. Age-Dependent Clinical Features and Prognosis of Covid-19 Patients, Tanaffos (2021)
47. Multiple Sclerosis Relapse After Covid-19 Vaccination: A Case Report-Based Systematic Review, Journal of Clinical Neuroscience (2022)
48. Late-Onset Multiple Sclerosis in Iran: A Report on Demographic and Disease Characteristics, Multiple Sclerosis and Related Disorders (2023)
49. Safety of Sinopharm Vaccine for People With Multiple Sclerosis: Study of Adverse Reactions and Disease Activity, Multiple Sclerosis and Related Disorders (2022)
50. Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009–2018, CNS Drugs (2021)